Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.2 kDa. The protein migrates as 35-45 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human B7-H3 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) is more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.
Immobilized Human B7-H3, His Tag (Cat. No. B73-H52E2) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).
Immobilized Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human B7-H3, His Tag (Cat. No. B73-H52E2) with a linear range of 0.01-0.156 μg/mL (Routinely tested).
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ifinatamab deruxtecan | I-DXd; MK-2400; DS-7300a; DS-7300; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Esophageal Neoplasms; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Lung Neoplasms | Details |
YL-201 | YL-201; YL201 | Phase 3 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Nasopharyngeal Carcinoma | Details |
HS-20093 | GSK-5764227; GSK’227; HS-20093; HS20093; GSK5764227 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd | Solid tumours; Ovarian Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Soft Tissue Neoplasms; Sarcoma; Osteosarcoma; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Breast Neoplasms; Neurofibrosarcoma; Prostatic Neoplasms; Neuroblastoma; Sarcoma; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Colonic Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Solid tumours; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hormone-Resistant Prostate Neoplasms; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Small Cell; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
7MW3711 | 7-MW-3711; 7MW3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DB-1311 | DB-1311; BNT-324 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
ILB-3101 | ILB-3101 | Phase 2 Clinical | Innolake Biopharm (Hangzhou) Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Wilms Tumor; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Urethral Neoplasms; Sarcoma, Ewing; Osteosarcoma; Prostatic Neoplasms; Neuroblastoma; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Abdominal Neoplasms; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours | Details |
SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Sarcoma, Clear Cell; Osteosarcoma; Retinoblastoma; Neuroblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma; Solid tumours; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Diffuse midline glioma; Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma | Details | |
124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
second generation anti-CD276 CAR T-cell therapy (Seattle Children's Hospital/Cureworks) | Phase 1 Clinical | Seattle Children'S Hospital | Rhabdomyosarcoma; Solid tumours; Hepatoblastoma; Neoplasms; Wilms Tumor; Neuroblastoma; Osteosarcoma; Retinoblastoma; Sarcoma; Sarcoma, Ewing; Carcinoma, Embryonal; Melanoma | Details | |
BCB-276 | BRAINCHILD-03; SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital, BrainChild Bio Inc | Sarcoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Choroid Plexus Neoplasms; Glioma; Neuroectodermal Tumors, Primitive; Diffuse Intrinsic Pontine Glioma; Neuroblastoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma, Clear Cell; Osteosarcoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Rhabdoid Tumor; Hepatoblastoma; Desmoplastic Small Round Cell Tumor; Carcinoma; Diffuse midline glioma; Rhabdomyosarcoma; Ependymoma; Medulloblastoma; Solid tumours | Details |
CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
GTB-5550 | GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™ | Phase 1 Clinical | University Of Minnesota | Solid tumours | Details |
WL276 CAR-T Cell Therapy(Immunochina Medical Science & Technology) | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Glioblastoma | Details | |
CAR.B7-H3 T cells (Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Glioblastoma | Details | |
[68Ga] B7H3 Affibody-BCH(Beijing Cancer Hospital) | Phase 1 Clinical | Beijing Cancer Hospital | Neoplasms | Details | |
BGB-C354 | BGB-C354 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
IBI-3001 | IBI-3001; IBI3001 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Solid tumours; Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Solid tumours; Central Nervous System Neoplasms; Mesothelioma; Brain Neoplasms; Glioma; Nervous System Neoplasms; Pleural Neoplasms; Pleural Effusion, Malignant | Details |
UTAA-06 | UTAA-06; UTAA06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Leukemia, Myeloid, Acute | Details |
B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Ovarian Neoplasms; Neuroblastoma; Osteosarcoma; Sarcoma; Nervous System Diseases | Details |
TX-103 | TX-103 | Phase 1 Clinical | Fuzhou Tcelltech Biological Science and Technology Co Ltd | Solid tumours; Glioma | Details |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
B7-H3-targeting CAR-T cell therapy | Phase 1 Clinical | Beijing Tiantan Hospital, Capital Medical University | Glioblastoma | Details | |
BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
TX-103-CAR-T | TX-103-CAR-T | Clinical | Union Hospital Affiliated To Fujian Medical University | Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma | Details |
Allogenic B7H3-targeting CAR-γδT Cell Therapy | QH104 Cell; QH-104 Cell | Clinical | Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) | Glioblastoma; Glioma | Details |
This web search service is supported by Google Inc.